Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind Study

ConclusionLong-term safety and OS were consistent with previous results and demonstrated no clinically meaningful differences between treatment groups.Trial registrationClinicalTrials.gov: NCT01989676 (21 November 2013); and EudraCT: 2013-001352-34 (18 December 2013).
Source: BioDrugs - Category: Drugs & Pharmacology Source Type: research